The Next Big Thing In Biotech: 2013 Outlook
Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
